Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BCL2L1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BCL2L1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BCL2L1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/BCL2L1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BCL2L1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/BCL2L1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BCL2L1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BCL2L1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123310 | Cervix | CC | regulation of apoptotic signaling pathway | 96/2311 | 356/18723 | 4.08e-14 | 3.05e-11 | 96 |
GO:009719110 | Cervix | CC | extrinsic apoptotic signaling pathway | 52/2311 | 219/18723 | 2.06e-06 | 6.34e-05 | 52 |
GO:200123610 | Cervix | CC | regulation of extrinsic apoptotic signaling pathway | 37/2311 | 151/18723 | 2.80e-05 | 4.65e-04 | 37 |
GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
GO:0072659 | Colorectum | AD | protein localization to plasma membrane | 122/3918 | 284/18723 | 2.86e-17 | 1.49e-14 | 122 |
GO:1990778 | Colorectum | AD | protein localization to cell periphery | 129/3918 | 333/18723 | 5.51e-14 | 1.15e-11 | 129 |
GO:0006839 | Colorectum | AD | mitochondrial transport | 102/3918 | 254/18723 | 1.87e-12 | 3.08e-10 | 102 |
GO:0097193 | Colorectum | AD | intrinsic apoptotic signaling pathway | 108/3918 | 288/18723 | 6.25e-11 | 6.41e-09 | 108 |
GO:1905475 | Colorectum | AD | regulation of protein localization to membrane | 73/3918 | 175/18723 | 3.37e-10 | 2.93e-08 | 73 |
GO:0045862 | Colorectum | AD | positive regulation of proteolysis | 129/3918 | 372/18723 | 4.04e-10 | 3.46e-08 | 129 |
GO:2001242 | Colorectum | AD | regulation of intrinsic apoptotic signaling pathway | 67/3918 | 164/18723 | 4.94e-09 | 3.16e-07 | 67 |
GO:1903076 | Colorectum | AD | regulation of protein localization to plasma membrane | 48/3918 | 104/18723 | 7.17e-09 | 4.36e-07 | 48 |
GO:1904375 | Colorectum | AD | regulation of protein localization to cell periphery | 54/3918 | 125/18723 | 1.52e-08 | 9.00e-07 | 54 |
GO:2001233 | Colorectum | AD | regulation of apoptotic signaling pathway | 119/3918 | 356/18723 | 2.14e-08 | 1.21e-06 | 119 |
GO:0034976 | Colorectum | AD | response to endoplasmic reticulum stress | 90/3918 | 256/18723 | 8.48e-08 | 4.28e-06 | 90 |
GO:0044403 | Colorectum | AD | biological process involved in symbiotic interaction | 99/3918 | 290/18723 | 1.02e-07 | 4.93e-06 | 99 |
GO:0010639 | Colorectum | AD | negative regulation of organelle organization | 114/3918 | 348/18723 | 1.41e-07 | 6.49e-06 | 114 |
GO:0010821 | Colorectum | AD | regulation of mitochondrion organization | 57/3918 | 144/18723 | 2.43e-07 | 9.92e-06 | 57 |
GO:0007006 | Colorectum | AD | mitochondrial membrane organization | 48/3918 | 116/18723 | 4.53e-07 | 1.72e-05 | 48 |
GO:0051701 | Colorectum | AD | biological process involved in interaction with host | 73/3918 | 203/18723 | 5.08e-07 | 1.88e-05 | 73 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517021 | Stomach | CAG with IM | Human immunodeficiency virus 1 infection | 29/640 | 212/8465 | 1.26e-03 | 8.93e-03 | 6.27e-03 | 29 |
hsa041152 | Stomach | CAG with IM | p53 signaling pathway | 12/640 | 74/8465 | 9.02e-03 | 4.86e-02 | 3.41e-02 | 12 |
hsa0501231 | Stomach | CAG with IM | Parkinson disease | 72/640 | 266/8465 | 7.97e-23 | 8.45e-21 | 5.93e-21 | 72 |
hsa0501431 | Stomach | CAG with IM | Amyotrophic lateral sclerosis | 75/640 | 364/8465 | 2.71e-16 | 9.58e-15 | 6.72e-15 | 75 |
hsa0502231 | Stomach | CAG with IM | Pathways of neurodegeneration - multiple diseases | 82/640 | 476/8465 | 4.27e-13 | 1.24e-11 | 8.67e-12 | 82 |
hsa0516631 | Stomach | CAG with IM | Human T-cell leukemia virus 1 infection | 38/640 | 222/8465 | 1.33e-06 | 2.12e-05 | 1.49e-05 | 38 |
hsa0541731 | Stomach | CAG with IM | Lipid and atherosclerosis | 37/640 | 215/8465 | 1.61e-06 | 2.43e-05 | 1.71e-05 | 37 |
hsa0513131 | Stomach | CAG with IM | Shigellosis | 33/640 | 247/8465 | 9.05e-04 | 6.85e-03 | 4.81e-03 | 33 |
hsa0517031 | Stomach | CAG with IM | Human immunodeficiency virus 1 infection | 29/640 | 212/8465 | 1.26e-03 | 8.93e-03 | 6.27e-03 | 29 |
hsa041153 | Stomach | CAG with IM | p53 signaling pathway | 12/640 | 74/8465 | 9.02e-03 | 4.86e-02 | 3.41e-02 | 12 |
hsa0501241 | Stomach | CSG | Parkinson disease | 72/633 | 266/8465 | 4.09e-23 | 4.31e-21 | 3.10e-21 | 72 |
hsa0501441 | Stomach | CSG | Amyotrophic lateral sclerosis | 75/633 | 364/8465 | 1.46e-16 | 5.13e-15 | 3.69e-15 | 75 |
hsa0502241 | Stomach | CSG | Pathways of neurodegeneration - multiple diseases | 82/633 | 476/8465 | 2.32e-13 | 6.67e-12 | 4.80e-12 | 82 |
hsa051664 | Stomach | CSG | Human T-cell leukemia virus 1 infection | 39/633 | 222/8465 | 3.66e-07 | 6.43e-06 | 4.62e-06 | 39 |
hsa0541741 | Stomach | CSG | Lipid and atherosclerosis | 37/633 | 215/8465 | 1.23e-06 | 1.95e-05 | 1.40e-05 | 37 |
hsa0513141 | Stomach | CSG | Shigellosis | 34/633 | 247/8465 | 3.60e-04 | 3.25e-03 | 2.34e-03 | 34 |
hsa0517041 | Stomach | CSG | Human immunodeficiency virus 1 infection | 29/633 | 212/8465 | 1.06e-03 | 7.60e-03 | 5.47e-03 | 29 |
hsa041154 | Stomach | CSG | p53 signaling pathway | 12/633 | 74/8465 | 8.29e-03 | 4.52e-02 | 3.25e-02 | 12 |
hsa0501251 | Stomach | CSG | Parkinson disease | 72/633 | 266/8465 | 4.09e-23 | 4.31e-21 | 3.10e-21 | 72 |
hsa0501451 | Stomach | CSG | Amyotrophic lateral sclerosis | 75/633 | 364/8465 | 1.46e-16 | 5.13e-15 | 3.69e-15 | 75 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Indole-based analog 2 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | NAVITOCLAX, ABT-263 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | antagonist | 252166532 | ABT 737 | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | PMID27744724-Compound-26 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | GOSSYPOL | GOSSYPOL | 19555126 |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | antagonist | 252166530 | VENETOCLAX | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | APG-1252 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ABT-737 | ABT 737 | 22386982,22747598 |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ABT-263 | NAVITOCLAX | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | CHEMBL443684 | NAVITOCLAX | |